Recruiting

Observational StudyCharacteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa

Sponsor:

Stanford University

Code:

NCT01019148

Conditions

Epidermolysis Bullosa Dystrophica

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether subjects could be candidates for treatment studies.

Conditions

Epidermolysis Bullosa Dystrophica

Study ID

NCT01019148

Start date

Nov 10, 2009

Status verified date

Apr, 2026

Completion date

Dec 31, 2029

Anticipated

Primary completion date

Dec 31, 2029

Anticipated

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Clinical diagnosis of RDEB by local dermatologist
7 years of age or older

Exclusion Criteria:

-Medical instability limiting ability to travel to Stanford University Medical Center

Study Design

Enrollment

70 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

Identification of subjects with Recessive Dystrophic Epidermolysis Bullosa [ Time Frame: 10 years ]

Central Contacts and Locations

Central contacts

Irene Bailey-Healy

(650) 721-7149 baileyhi@stanford.edu

Locations

Stanford University School of Medicine

Recruiting

Stanford, California, United States, 94305

Contacts

Irene Bailey-Healy

(650) 721-7149 baileyhi@stanford.edu

Principal Investigator:

Jean Tang, MD, PhD

More Information

Sponsor

Stanford University

Last update posted

Apr 24, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Stanford University on 2026-04-24.